[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
[HTML][HTML] Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent …
Methods to assess research misconduct in health-related research: A scoping review
Objective To give an overview of the available methods to investigate research misconduct
in health-related research. Study Design and Setting In this scoping review, we conducted a …
in health-related research. Study Design and Setting In this scoping review, we conducted a …
[HTML][HTML] Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2022 - ncbi.nlm.nih.gov
Background Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …
[HTML][HTML] Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - The Lancet Respiratory Medicine, 2021 - Elsevier
Background Colchicine has been proposed as a treatment for COVID-19 based on its anti-
inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients …
inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
J Chalmers, H Abo-Leyah, H Loftus, M Spears… - …, 2021 - discovery.dundee.ac.uk
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
[HTML][HTML] Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background Azithromycin has been proposed as a treatment for COVID-19 on the basis of
its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin …
its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin …
Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel
MA Psotka, WT Abraham, M Fiuzat, G Filippatos… - Journal of the American …, 2020 - jacc.org
Abstract The coronavirus disease-2019 (COVID-19) pandemic has profoundly changed
clinical care and research, including the conduct of clinical trials, and the clinical research …
clinical care and research, including the conduct of clinical trials, and the clinical research …
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, PW Horby… - MedRxiv, 2021 - medrxiv.org
Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the …
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the …
Increasing value and reducing waste in biomedical research regulation and management
RAS Salman, E Beller, J Kagan, E Hemminki… - The Lancet, 2014 - thelancet.com
After identification of an important research question and selection of an appropriate study
design, waste can arise from the regulation, governance, and management of biomedical …
design, waste can arise from the regulation, governance, and management of biomedical …